Patients in several states have reported going to fill routine prescriptions for Lantus SoloStar insulin pens and leaving without them. Sanofi has confirmed it is experiencing a period of intermittent supply of the pens. And Lantus is not listed in the FDA's Drug Shortages Database.

Those three facts sound contradictory and are not. Understanding why explains both what is happening and why the regulatory system is not responding the way patients might expect.

Before anything else, the practical point that matters most: if you cannot fill your insulin prescription, contact your prescriber promptly rather than stretching what you have. Insulin rationing is dangerous and can cause serious harm quickly. Alternatives to this specific pen exist and are in supply.

Two different questions with two different answers

FDA declares a drug shortage based on whether the total national supply of a drug meets demand, assessed across all therapeutically equivalent versions from all manufacturers. Insulin glargine, the molecule in Lantus, is currently available from several sources. Lilly's Basaglar and Rezvoglar are on the market, generic insulin glargine is available from Winthrop and others, and Sanofi's own Toujeo, a more concentrated version of the same molecule, is available.

By that standard, insulin glargine is not in shortage. Enough of the drug exists nationally.

The question a patient is asking is different: can I get the specific product I have been using, at my pharmacy, today. The answer to that has plainly been no for a meaningful number of people. One tracker that samples pharmacy stock reported an availability score of 10% for Lantus based on 112 pharmacy checks over 30 days, against 619 patient searches in the same period. Those are not FDA data and the methodology is proprietary, so the figure is a signal rather than an official measure, but it is consistent with what pharmacists and patients are describing.

The gap between those two questions is not a bureaucratic oversight. It reflects a definition that was written to answer a national supply question, and it has a real consequence: shortage listing is what activates regulatory flexibilities, including expedited review of alternative supply, temporary importation, and certain compounding allowances. When a product is hard to find but the molecule is not formally short, none of those tools engage. The situation is handled entirely through substitution at the pharmacy counter, which works for many patients and not for all of them.

What actually caused this

The trigger was the exit of a competitor, not a manufacturing failure at Sanofi.

Biocon discontinued Semglee, the interchangeable biosimilar of Lantus, at the end of December 2025. Semglee had been widely adopted, and many insurance formularies had made it the preferred insulin glargine. When it left the market, that demand did not disappear. It moved onto the remaining products, including brand Lantus, and did so while insurance plans were still updating formularies. The American Society of Health-System Pharmacists lists Lantus SoloStar pens among affected insulin glargine presentations, alongside notes on discontinued and constrained products across the category.

That is a demand shock landing on a product category that cannot respond quickly. Insulin glargine is a biologic produced by fermentation using engineered bacteria, then purified and filled into devices under sterile conditions. Production runs are planned far in advance and capacity cannot be scaled up in weeks the way a tablet press can. A manufacturer forecasting normal demand a year ago has limited ability to absorb another company's abandoned market share on short notice.

This has happened before in the same product, in the mirror-image direction. When Basaglar entered the market in late 2016, Sanofi adjusted production volumes and a supply gap opened during the transition. FDA shortage staff observed at the time that demand fluctuations related to competitive market entry can paradoxically create short-term supply disruptions. Entry destabilized supply then. Exit is destabilizing it now. Both are symptoms of a category with few manufacturers, long lead times, and no slack.

The uncomfortable tension underneath

There is a policy question here that deserves stating carefully, because it is genuinely difficult rather than a matter of blame.

Semglee was a policy success story. It was the first interchangeable biosimilar insulin, approved specifically to introduce competition into a market long criticized for high prices, and it gained real share. In the same period, Sanofi reduced the Lantus list price by 78% and capped out-of-pocket costs at $35 a month for commercially insured patients. That price reduction is unambiguously good for people who need insulin, and it was the outcome years of public pressure was aimed at.

It also narrowed the space a biosimilar competes in. Biocon has not attributed its discontinuation to any single cause, and asserting a direct link would go beyond what the public record supports. But the structural tension is real and worth naming: in a low-margin biologic market with high manufacturing costs, aggressive price competition can make the competitors whose entry created that competition commercially unviable. If they exit, the market becomes more concentrated, and a more concentrated market is a more fragile one. Lower prices and resilient supply are both goals, and this is a case where pursuing the first hard may have consequences for the second.

That is not an argument against reducing insulin prices. It is an argument that a market with two or three viable manufacturers of an essential medicine needs someone watching the number of manufacturers as a separate variable from the price.

Why "switch to an alternative" is harder than it sounds

Clinically, insulin glargine products are largely interchangeable, and for many patients moving to Basaglar, Rezvoglar, or a generic is straightforward. The reasons it is not always simple are worth understanding, because they explain the frustration in these reports.

Insulin pens differ in physical operation. Dose dials have different resistance and different audible clicks, which matters a great deal for patients with visual impairment who count clicks to dose. Injection force, needle compatibility, priming steps, and the amount of pressure needed to complete a dose all vary between devices. Someone who has used one pen for years has muscle memory built around it, and switching devices introduces a window where dosing errors are more likely, in a medication where an error in either direction is consequential.

There is also coverage friction. An available alternative may not be the one a patient's plan prefers, which can mean a new prior authorization, a different copay, or a delay measured in days at exactly the moment supply is tight.

None of that makes switching wrong. It makes it a clinical decision that needs a prescriber involved, rather than a substitution that resolves itself at the counter.

What to do if you are affected

The endocrinologist quoted in the initial reporting gave the correct guidance, and it is worth repeating in full. Patients unable to refill should contact their health care provider as soon as possible, should not go without insulin because it can be dangerous, and should discuss whether a generic insulin glargine or another appropriate alternative is an option, while checking with their insurer about coverage differences and savings programs.

A few practical additions. Call ahead to several pharmacies rather than traveling between them, since stock varies locally and pharmacists can often check regional availability. Ask your pharmacist directly whether an equivalent product is in stock, since they can frequently see options a patient cannot. Do not stretch, skip, or dilute doses to make a supply last, and tell your prescriber immediately if you are close to running out.

One time-sensitive note for a different product: Lilly is discontinuing Basaglar Tempo pens, which are available through July 27, 2026. The insulin in pens already dispensed remains usable until its expiration date, but anyone relying on that specific device should speak with their prescriber about what comes next.

The larger point

Insulin glargine has appeared on shortage tracking databases repeatedly since 2011, and the causes have varied while the underlying condition has not: an essential medicine, made by a small number of manufacturers, with production timelines measured in months and no capacity buffer for a sudden shift in demand.

That fragility is invisible in ordinary times and becomes visible whenever one participant changes course. The current disruption was set off by a competitor leaving rather than by anything going wrong at the remaining manufacturers, which is precisely why the formal shortage definition does not capture it. For the system, national supply is adequate. For a person standing at a pharmacy counter without the pen they have used for years, that distinction does not help much, and closing the gap between those two realities is the part of this problem that no current regulatory tool is designed to address.

Further reading